In recent years, biologics targeting type 2 inflammation, including IL-4, IL-5, IL-13, and IgE, have demonstrated efficacy in treating severe cases of CRSwNP that are resistant to glucocorticoids and surgical interventions. This evidence concerns the gene IL13 and chronic rhinosinusitis with nasal polyps.